Immunotherapy in NSCLC
Advertisement
Ivonescimab plus chemotherapy “demonstrated strongly positive results” as a first-line treatment for advanced squamous ...
A recent study may provide a "clearer, more individualized" understanding of progression risk after discontinuation.
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Subcutaneous pembrolizumab may be “a viable treatment option" in indications where pembrolizumab is approved.
Andrea Riccardo Filippi, MD, presented survival data from the final PACIFIC-R data extraction with over 5 years of follow-up.
The study included patients with advanced NSCLC with PD-L1 expression of at least 50% and no EGFR, ALK, or ROS abberations.
Investigators of a phase 2 study uncovered a biomarker that may be associated with major pathologic response in this setting.
The study investigators concluded that ivonescimab “might represent another treatment option in the first-line setting."
Researchers evaluated if there was a link between pretreatment systemic immune inflammation index levels and outcomes.
The therapy is currently under evaluation in phase 1 and phase 2 trials.
It is the "first and only neoadjuvant-only immuno-oncology therapy" to show a significant OS benefit in this setting.
The study is comparing ivonescimab plus platinum-based chemotherapy with tislelizumab plus platinum-based chemotherapy.
The study aims to confirm safety and efficacy findings from the phase 2 QUILT 3.055 trial.
Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in NSCLC.
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
The trial is investigating nogapendekin alfa inbakicept-pmln in combination with immune checkpoint inhibitor therapy.
The therapy is now the “first and only subcutaneously administered PD-1 inhibitor," officials said in an announcement.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.